Finding Reliable 3%+ Dividends in Today’s Market: AbbVie Inc.
June 23, 2016 at 12:08 PM EDT
One of ABBV’s top earning drugs, Humira, will have its US patent expire in December 2016 and in April 2018 in the EU. Humira is approved for treatments in over 60 countries, and represents roughly 60% of ABBV’s current revenue uptake.
